● TIER 3 — Information onlyGRADE C (LR3) / A (mecasermin)GH secretagogues & GH axis
IGF-1 LR3 / Mecasermin
IGF-1 analogs. Research verification: Yes (TGA pending). 1 human study record(s) in the FitClinicMD studies database. Approval note: mecasermin (Increlex) is FDA-approved for severe primary IGF-1 deficiency in children (approved 2005). The page-level Tier 3 rating applies to IGF-1 LR3, which is unapproved and not compoundable, and to any non-approved use of mecasermin.
GOALS · Muscle / body composition
FDA status
Mecasermin (Increlex) approved for severe primary IGFD in children; LR3 unapproved.
Compounding (503A/503B)
LR3 not compoundable.
DEA
Not controlled.
WADA (sport)
S2.3 Growth factors & modulators (IGF-1/mecasermin & analogues, MGFs, thymosin-β4 & derivatives e.g. TB-500, HGF)
Mechanism
IGF-1R agonist.
Human evidence · 1
Mecasermin long-term pediatric review. Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency.
Reference only. This page summarizes publicly available regulatory and research information about IGF-1 LR3 / Mecasermin. It is not a prescription, an endorsement, or an offer to dispense, and regulatory status can change. Clinicians should verify current status before prescribing or compounding.